BioPharmaTrend.com

In this interview Andrii Buvailo, Ph.D. talks Tim Smith, co-founder and CTO of Medable, Inc to shed light on some ways to improve efficiency of clinial trias via novel digital platform. Link to full interview in the comments 👇 #clinicaltrials #biopharmatrend

In yesterday's issue of Weekly Tech+Bio: • NOETIK Secures $40 Series A, Unveils First-of-its-kind Data Atlas for Cancer Research: Noetik raised $40M in Series A funding to advance its OCTO platform, an AI engine that simulates patient-specific cancer biology using multimodal data from tumor samples. • From the Trenches of the 11th Aging Research & Drug Discovery Meeting Reporting from the 11th ARDD Meeting in Copenhagen. Including a brief list of smaller companies that stand out as particularly promising for partnerships and investment opportunities. • Towards "Synthetic Immune System": Maxwell Biosciences is pioneering CLAROMER technology—synthetic molecules mimicking natural antimicrobial peptides to combat viruses and bacteria. Their approach targets pathogen lipid membranes, offering broad-spectrum potential against resistant infections, with preclinical success and ongoing partnerships with U.S. military research agencies. See the full write-up in the comments!

We are attending the world’s leading event in aging research and age-related drug discovery at the University of Copenhagen, where experts are presenting on critical advancements in the field. The #ARDD2024 conference is offering a deep exploration of strategies to extend healthspan and lifespan beyond lifestyle changes, focusing on preclinical and clinical candidates that could redefine aging. So far today, we’ve gained valuable insights from Jens Juul Holst on GLP-1 receptor agonists, Marie Kveiborg highlighted the Novo Nordisk Foundation’s approach to translating biomedical discoveries into clinical practice, while Lykke Sylow shed light on the new targets for muscle mass preservation in healthy aging. We’ve also heard from Collin Ewald on longevity through DAF-2 degradation, and Anders Naar on RNA medicines for aging-related diseases. Most recently, Christina Camell presented on targeting immune function in older organisms, a critical area for enhancing healthspan. Many more presentations to come, promising to further broaden our understanding of aging and longevity. We’re excited to continue learning and seeing how these developments will influence the field in the coming years. Stay tuned for more updates from ARDD 2024. Live streaming from the main hall is available on the University of Copenhagen's website. #ARDD2024 #LongevityResearch #Healthspan #Biotech #Aging

We are excited to announce an official media partnership of this year’s Disruptive Technology for Clinical Trials Summit, taking place on 8 October 2024, in Boston, MA, USA.   The pharmaceutical industry is experiencing a significant shift towards embracing technology-driven solutions to improve efficiency, streamline processes, and foster innovation in clinical research.   As technology continues to rapidly evolve, we invite clinical trials technology leaders to join us at the Disruptive Technology for Clinical Trials Summit to collaborate with their peers, learn how to overcome key challenges, and enable patient-centric, efficient, and innovative clinical trials.   To find out more about the summit and to register, use our 15% discount code BIOPHARMA15: https://lnkd.in/diVEjbaD   #AMGWorld #DisruptiveClinicalTrials #Technology #Boston

This week in "Where Tech Meets Bio", Recursion makes headlines with its $688 million acquisition of Exscientia, signaling consolidation in the AI-driven drug discovery space. • Basecamp Research is breaking new ground with a partnership in Cameroon to advance digital sequence information, while 23andMe shifts focus to the booming GLP-1 market, launching a telehealth weight loss program that leverages their genetic data for personalized treatments. • The Kaggle contest by Leash Bio has exposed critical limitations in current AI models for protein binding, underscoring the need for larger datasets to achieve breakthroughs. • Meanwhile, Neuralink has successfully implanted its brain-computer interface in a second patient, allowing control of digital devices through thought alone, with plans to extend the trial to additional patients this year. • At Wyss Institute at Harvard University, latest innovation in 3D-printed blood vessels is moving us closer to the reality of implantable human organs. And don’t miss this week’s takeaway—where we explore the split biotech financing landscape and reveal why certain modalities like antibody-drug conjugates are attracting massive investments, while others are facing significant challenges. Curious? See more in the comment section to get all the details, and more.

BiopharmaTrend at ARDD 2024! We are excited to announce that BiopharmaTrend is a proud media partner for the 11th Aging Research & Drug Discovery Meeting (ARDD). Our CEO, Andrii Buvailo, Ph.D., will be attending this leading event, where longevity pioneers like Insilico Medicine’s Alex Zhavoronkov and Novo Nordisk Foundation’s Marie Kveiborg, David A. Sinclair A.O., Ph.D., Garri Zmudze, and many more will gather to advance the future of longevity research. Leaders in the aging and longevity field will present the latest breakthroughs in understanding the molecular, cellular, and organismal basis of aging, along with cutting-edge interventions aimed at extending healthspan and lifespan. Join us as we explore the discoveries that are shaping a healthier, longer future. Stay tuned for exclusive insights and on-site reporting from ARDD 2024! #ARDD2024 #LongevityScience #AgingResearch #DrugDiscovery

The race to redefine obesity treatment is heating up, with $100 billion at stake—will the current giants hold their ground, or are new challengers ready to disrupt the market? Daniel Chancellor, VP at Norstella, highlights that the obesity drug market is on track to reach $100 billion by 2030, driven by innovative treatments and expanding applications for obesity drugs in related conditions like NASH and chronic kidney disease. While Novo Nordisk and Eli Lilly and Company currently dominate, new competitors and alternative formulations could reshape the landscape. Full article in the comment section. #obesity #biotech #drugdevelopment

What happened last week? Main topics from latest Weekly Tech+Bio Highlights: • Recursion Acquires AI Biotech Exscientia for $688M: Recursion expands its AI-driven drug discovery capabilities by acquiring Exscientia. • Roche's $1.9B Flatiron Health Gamble: Roche is considering selling or restructuring Flatiron Health, a cancer data company acquired in 2018, due to declining sales and challenges in business relationships. • 3D-Printed Lung Model for COVID-19 Research: Pohang University of Science and Technology and Korea Research Institute of Chemical Technology (KRICT) have developed a 3D bioprinted lung model that better mimics human lung functions, aiding in more accurate testing of COVID-19 treatments. • New AI Framework Tackles Medical Hallucinations: Mendel.ai and University of Massachusetts Amherst have introduced a framework to detect hallucinations in AI-generated medical summaries. More in the latest issue of Where Tech Meets Bio (Substack Newsletter), see the link in the comments.

In latest Weekly Tech+Bio Highlights, we take a look at: • How to Differentiate Hype from Substance in the AI Drug Discovery Space? Dr. Alex Zhavoronkov of Insilico Medicine outlines ten questions to evaluate AI drug discovery companies, focusing on clinical progress, target novelty, and financial stability. • How to Define Intelligence and Consciousness for In Silico and Organoid-based Systems? A global initiative led by Cortical Labs seeks to standardize definitions for intelligent systems across disciplines using a collaborative Delphi method. • GSK, Flagship Partner for Drug Discovery GSK partners with Flagship Pioneering to develop up to ten new drugs and vaccines, potentially generating over $7 billion for Flagship and its companies. • 3D-Printing mRNA Vaccines Triastek, Inc. and BioNTech SE collaborate to develop 3D-printed oral RNA therapeutics, optimizing delivery and absorption across the gastrointestinal mucosa. • The New Milestone for Regenerative Medicine Magellan Stem Cells' allogeneic mesenchymal stem cell therapy, MAG200, shows significant efficacy in Phase I/II trials for knee osteoarthritis, improving pain and cartilage quality. • 12 Emerging Neurotech Startups to Keep an Eye On in 2024 A list of promising neurotech startups, including Arctop, Diagnostic Biochips, Inc., Neurable, and more, developing innovative technologies in brain-computer interfaces and cognitive health. Upcoming event: Join us at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) will be held on August 26-30 in Copenhagen, Denmark! For a more comprehensive review in our weekly rubric, see the link in the comments.

10 Weeks Till the FormuTech Summit! Join top industry leaders from Sanofi, Merck Life Science, Moderna, and more for an insightful two-day event about mRNA Development & LNP Formulations. 📅 Date: October 17-18, 2024 📍 Location: Madrid, Spain 🔬 What to Expect? 20+ Expert Presentations on cutting-edge topics: • Latest advancements in mRNA process development. • LNP characterization for better efficacy and safety. • Solutions to global manufacturing challenges. • Expanding LNP applications in gene editing and CRISPR. • Optimizing CMC roadmaps for consistent mRNA therapeutic quality. • Navigating technical and regulatory landscapes. • Exclusive Insights into GMP manufacturing of Lipid Nanoparticles. 👉 Link to the event will be posted in the comments. #FormuTech2024 #mRNADevelopment #LNPFormulations #Biotech #GeneEditing #CRISPR #GlobalManufacturing